From the outside looking in it must look like there has never been a better time to be developing ADCs. We have seen unprecedented growth and huge investment that has somewhat shielded the ADC field from otherwise adverse market conditions. ADCs have flourished while most other therapeutic modalities have had major setbacks and an exodus of funding.
But is it all sunshine and rainbows? Things are getting more challenging, especially for smaller biotechs and recent entrants into the space. The gold rush mentality of the last few years has resulted in extreme concentration of very similar assets. Developers face pressure to derisk their ADCs through use of clinically validated targets and payloads but when everyone is using these targets and payloads, how do you differentiate?
Key Insights:
- How do you find balance between validation and innovation for an ADC pipeline?
- What does the competitiveness of the space mean for an R&D team? To what extent should data from other ADCs be used to benchmark your own studies?
- Is sentiment changing around the strong preference for validated targets and payloads? Is the risk of not being differentiated now outweighing the risk of trying something new? Do investors see it the same way?
Why Attend?
This is a brilliant opportunity to be privy to a discussion tackling these issues and more with our panel of KOLs. Learn from those with both experience of leading ADC programs at their previous organisations and their finger on the pulse through their current consulting work for multiple ADC Biotechs.
Webinar Leaders
Jake Morris
Moderator
Commercial Manager, Beacon
Kati Räsänen
Speaker
Independent Consultant
Greg Adams
Speaker
Independent Consultant – Former CSO at Elucida Oncology Inc
Dowdy Jackson
Speaker
CEO at Jackson Consulting Group Inc
You May Also Be Interested In…
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
